Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adenosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 3/20 | 0.61 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.61 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 0.61 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 0.61 |
| ▸ | DTYMK | P23919 | 4/20 | 0.76 |
| ▸ | DNMT1 | P26358 | 7/20 | 0.62 |
| ▸ | DNMT3B | Q9UBC3 | 4/20 | 0.62 |
| ▸ | FPR2 | P25090 | 3/20 | 0.62 |
| ▸ | DPP4 | P27487 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.61 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.61 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.61 |
| ▸ | GAPDH | P04406 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | STAT6 | P42226 | 1/20 | 0.61 |
| ▸ | PI4KA | P42356 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine SCHEMBL6863617 | 1.00 | DTYMK (0.76) | DTYMKDNMT1DNMT3BFPR2ADORA3 | |
| Adenosine SCHEMBL8846731 | 0.94 | DTYMK (0.69) | DTYMKDNMT1DNMT3BFPR2ADORA3 | |
| Deoxyadenosine SCHEMBL20819422 | 0.93 | DTYMK (0.67) | DTYMKDNMT1DNMT3BFPR2SMN1; SMN2 | |
| Adenosine SCHEMBL23835231 | 0.92 | DTYMK (0.66) | DTYMKDNMT1DNMT3BFPR2ADORA3 | |
| Adenosine SCHEMBL7101792 | 0.92 | DTYMK (0.66) | DTYMKDNMT1DNMT3BFPR2ADORA3 | |
| Adenosine SCHEMBL1549514 | 0.92 | DTYMK (0.66) | DTYMKDNMT1DNMT3BFPR2ADORA3 | |
| Adenosine SCHEMBL3194871 | 0.89 | DTYMK (0.91) | DTYMKSMN1; SMN2 | |
| Adenosine SCHEMBL574772 | 0.89 | DTYMK (0.63) | DTYMKADORA3DPP4MEN1SLC28A1 | |
| Adenosine SCHEMBL9710357 | 0.89 | DTYMK (0.66) | DTYMKDNMT1DNMT3BFPR2ADORA3 | |
| Adenosine SCHEMBL10496357 | 0.89 | DTYMK (0.69) | DTYMKDNMT1DNMT3BFPR2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11732286-B2 | T5 exonuclease-based method to identify DNA topoisomerase inhibitors | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2023-08-22 | — | — | US | claimed |
| US-20220170070-A1 | T5 EXONUCLEASE-BASED METHOD TO IDENTIFY DNA TOPOISOMERASE INHIBITORS | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2022-06-02 | — | — | US | claimed |
| US-20220119858-A1 | T5 EXONUCLEASE-BASED METHOD TO IDENTIFY DNA TOPOISOMERASE INHIBITORS | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2022-04-21 | — | — | US | claimed |
| US-11268129-B1 | T5 exonuclease-based method to identify DNA topoisomerase inhibitors | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2022-03-08 | — | — | US | claimed |
| US-10150987-B2 | Labeled circular DNA molecules for analysis of DNA topology, and topoisomerases and for drug screening | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2018-12-11 | — | — | US | claimed |
| US-20180135112-A1 | LABELED CIRCULAR DNA MOLECULES FOR ANALYSIS OF DNA TOPOLOGY, AND TOPOISOMERASES AND FOR DRUG SCREENING | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2018-05-17 | — | — | US | claimed |
| US-9890416-B2 | Labeled circular DNA molecules for analysis of DNA topology, and topoisomerases and for drug screening | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2018-02-13 | — | — | US | claimed |
| EP-2432314-B1 | MOUSE MODELS CARRYING A KNOCK-OUT MUTATION OF THE QPCTL-GENE | PROBIODRUG AG (DE) | 2017-12-20 | — | — | EP | claimed |
| US-20170096701-A1 | LABELED CIRCULAR DNA MOLECULES FOR ANALYSIS OF DNA TOPOLOGY, AND TOPOISOMERASES AND FOR DRUG SCREENING | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2017-04-06 | — | — | US | claimed |
| US-20130183765-A1 | Ultraviolet and High-Performance Liquid Chromatography Methods for the Evaluation of Sunscreen Efficacy | Sena Research Incorporated (US) | 2013-07-18 | — | — | US | claimed |
| WO-2012037158-A2 | ULTRAVIOLET AND HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY METHODS FOR THE EVALUATION OF SUNSCREEN EFFICACY | SENA RESEARCH, INCORPORATED (US) | 2012-03-22 | — | — | WO | claimed |
| EP-4330384-A1 | ENZYME COMPOSITION WITH AT LEAST TWO DIFFERENT THERMOSTABLE POLYPEPTIDES HAVING TYPE II DNA METHYLTRANSFERASE ACTIVITY | Blucon Biotech GmbH (DE) | 2024-03-06 | — | — | EP | disclosed |
| CN-117441014-A | Enzyme composition having at least two different thermostable polypeptides having type II DNA methyltransferase activity | 布鲁克生物科技公司 | 2024-01-23 | — | — | CN | disclosed |
| US-20230364057-A1 | BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. | 2023-11-16 | — | — | US | disclosed |
| US-11732286-B2 | T5 exonuclease-based method to identify DNA topoisomerase inhibitors | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2023-08-22 | — | — | US | disclosed |
| US-6270962-B1 | DECREASING INCIDENCE OF DNA(DEOXYRIBO NUCLEIC ACID) POLYMERASE STOPS OR PAUSING OCCURRING IN A REACTION MIXTURE CONTAINING A DNA POLYMERASE BY ADDING NITROGEN CONTAINING ORGANIC COMPOUNDS (E.G: BETAINE, TRIMETHYLAMINE N-OXIDE, ETC) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-08-07 | — | — | US | disclosed |
| WO-2001003686-A2 | INHIBITORS OF STAPHYLOCOCCUS SARA PROTEIN AND THEIR USE IN TREATING STAPHYLOCOCCAL INFECTIONS | BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2001-01-18 | — | — | WO | disclosed |
| EP-0742838-A4 | METHODS FOR THE ELIMINATION OF DNA SEQUENCING ARTIFACTS | UNIV CALIFORNIA (US) | 2000-01-05 | — | — | EP | disclosed |
| EP-0742838-A1 | METHODS FOR THE ELIMINATION OF DNA SEQUENCING ARTIFACTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-11-20 | — | — | EP | disclosed |
| WO-1995020682-A1 | METHODS FOR THE ELIMINATION OF DNA SEQUENCING ARTIFACTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364057-A1 | BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF | TOP1, DNA2, TOP2A | ADORA3 3677/4885ADORA2A 3990/4885ADORA2B 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.